People get down with various illnesses, require medical help and medicines. Finding specialized medical treatment and drugs is not an easy task. Internet is right place where one can easily find this information and there are many sites available provide great insight on a particular disease and its treatments. There are some diseases that can be dangerous and appears in very rare cases. To treat such diseases, there are special drug invented which are priced in the $300,000-$360,000 annual cost range. Here we are providing you list of most expensive drugs in the world that can treat most deadly diseases.
Glybera is one of the most expensive drugs and it is a therapy that helps the patient to get restores enzyme activity. Restoring the enzyme activity in body is not easy because removing fat-carrying chylomicron particles in the intestines with following a fat-containing meal requires special treatment. This therapy is expensive but it it treats an extremely rare condition known as familial lipoprotein lipase deficiency. This deficiency occur only one in 1 million people. This treatment is required by only around 150 to 200 people in the EU. The treatment is given to patient by a one-time series of up to 60 intramuscular injections in patients’ legs. When you decide to get this therapy done you have to get ready to pay a 1.1 million euro price tag for Glybera. It is one of the major medicines at high price.
Read also 10 Ways For Healthy Relationships
Alexion Pharmaceuticals’ introduced Soliris and it is so far one of the most expensive medicine in the world for years. Many of you must be thinking that Soliris would be on first on the list but it may come as a surprise to many. Last year in USA Soliris had a wholesale cost of nearly $537,000. Recently the Patented Medicines Price Review came up with a surprise figure of this medicine in Canada where it gets as high as $700,000 per patient. Soliris is important because it helps in treating two major illnesses. It can treat paroxysmal nocturnal hemoglobinuria (PNH), and also treat atypical hemolytic uremic syndrome. Both the illnesses are rare in nature and thus, this medicine command such a high price tag. With this medicine, patients with PNH often live for 10 to 15 years following their diagnosis.
FiercePharma provided a data in which BioMarin Pharmaceutical‘s gets the third place with Naglazyme at an annual cost approaching a half-million dollars. It is one of the most expensive medicines in the world and deserves to be in the list. It is one of the medicines that are prescribed to a few dozen patients on a per year basis. According to a data provided by EvaluatePharma, very few patients require this medicine. Naglazyme is an enzyme, which is a therapy designed to treat a disease known as mucopolysaccharidosis type VI. This disease is also known as Maroteaux-Lamy syndrome. It is a progressive disease, which cause organ enlargement and skeletal abnormalities. People diagnose with this disease leads to shortened life expectancies for those diagnosed.
BioMarin Pharmaceutical has introduced Vimizim to treat a rare disease and that makes it an expensive disease. This deserve to the fourth-most expensive drug in the world. It is one of the expensive diseases with $380,000 per year cost. This medicine is helpful in treating Morquio A syndrome and the disease is treated by an enzyme replacement therapy that’s given as a weekly infusion. This disease is deadly and characterized by the body’s inability to break down long-chain sugar molecules. As per a report it has been seen that 800 people have Morquio A in the United States, 3,000 people developed this disease in world market. As per the analytical study the medicine is required by less patients but its relatively small market potential. This medicine could generate up to a half-billion in sales annually at its peak for BioMarin.
Elaprase deserve to be in the list as fifth-most expensive drug in the world. Shire‘s introduced Elaprase treatment to the world. This medicine work as an enzyme replacement therapy designed to treat patients with mucopolysaccharidosis II, or Hunter syndrome. As per the report generated, this medicine ran $375,000 per year on a wholesale level. But later the price has fallen since that time with no added competition to the Hunter syndrome indication. People who are down with this disease, patient lead to progressive organ decline, specifically of the heart, lungs, liver, and spleen. It is also one of the rarest disease and as per the EU reported one case per every 140,000-156,000 births, which is quite rare.